Combination of Inhaled DNase, Baricitinib and Tocilizumab in Severe COVID-19

NCT05279391 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

150

Enrollment

OTHER

Sponsor class

Conditions

COVID-19 Severe Respiratory Failure

Interventions

DRUG: Dexamethasone
DRUG: Low molecular weight heparin
DRUG: Anakinra 100Mg/0.67Ml Inj Syringe
DRUG: Tocilizumab
DRUG: Baricitinib
DRUG: Dornase Alfa Inhalant Product

Sponsor

Democritus University of Thrace